MannKind Corporation

MannKind is a biopharmaceutical company focused on development and commercialization of therapeutic products for diseases such as diabetes. The company’s lead product, Afrezza® (insulin human [rDNA origin]) inhalation powder, is an ultra-rapid-acting insulin being developed for the treatment of adult patients with type 1 or type 2 diabetes. It is a drug-device combination product, consisting of AFREZZA inhalation powder, pre-metered into single-use cartridges, and a light, discreet and easy-to-use inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the bloodstream.